Challenging issues in tuberculosis in solid organ transplantation

Clinical Infectious Diseases

Volumn 57, Issue 10, 2013, Pages 1473-1482

  Horne, David J ^a   Narita, Masahiro ^a,d   Spitters, Christopher L ^b,d   Parimi, Soumya ^a   Dodson, Sherry ^c   Limaye, Ajit P ^b  

^a Divisions of Pulmonary and Critical Care Medicine   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d Tuberculosis Control Program   (United States)

Author keywords

Solid organ transplant; Tuberculosis

Indexed keywords

ALANINE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN; GAMMA INTERFERON; ISONIAZID; PREDNISONE; RIFABUTIN;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BRAIN BIOPSY; BRONCHOSCOPY; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOKINE RELEASE; END STAGE LIVER DISEASE; FEMALE; FIBROSING ALVEOLITIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; LATENT TUBERCULOSIS; LUNG LAVAGE; LUNG TUBERCULOSIS; MALE; MEDICAL HISTORY; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; ORGAN DONOR; ORGAN TRANSPLANTATION; PHILIPPINES; POLYMERASE CHAIN REACTION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RESPIRATORY FAILURE; RISK FACTOR; SOLID ORGAN TRANSPLANTATION; THORAX RADIOGRAPHY; TRACHEOBRONCHIAL TOILET; TUBERCULIN TEST; TUBERCULOSIS; UNITED STATES;

SOLID ORGAN TRANSPLANT; TUBERCULOSIS;

FEMALE; HUMANS; MALE; MIDDLE AGED; TRANSPLANTATION; TUBERCULOSIS;

EID: 84887882561     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit488     Document Type: Article

References (53)

1. Munoz P, Rodriguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis 2005; 40: 581-7.
2. Bumbacea D, Arend SM, Eyuboglu F, et al The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Eur Respir J 2012; 40: 990-1013.
3. Aguado JM, Torre-Cisneros J, Fortun J., et al Tuberculosis in solidorgan transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology. Clin Infect Dis 2009; 48: 1276-84.
4. Subramanian AK, Morris MI Mycobacterium tuberculosis Infections in Solid Organ Transplantation. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2013; 13(SUPPL. 4): 68-76.
5. Lopez de Castilla D, Schluger NW. Tuberculosis following solid organ transplantation. Transpl Infect Dis 2010; 12: 106-12.
6. Singh N, Paterson DL Mycobacterium tuberculosis infection in solidorgan transplant recipients: impact and implications for management. Clin Infect Dis 1998; 27: 1266-77.
7. Torre-Cisneros J., Doblas A, Aguado J.M., et al Tuberculosis after solidorgan transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort. Clin Infect Dis 2009; 48: 1657-65.
8. Canet E, Dantal J, Blancho G., Hourmant M, Coupel S. Tuberculosis following kidney transplantation: clinical features and outcome. A French multicentre experience in the last 20 years. Nephrol Dial Transplant 2011; 26: 3773-8.
9. Klote MM, Agodoa LY, Abbott K. Mycobacterium tuberculosis infection incidence in hospitalized renal transplant patients in the United States, 1998-2000. Am J Transplant 2004; 4: 1523-8.
10. Dye C, Scheele S, Dolin P., Pathania V, Raviglione MC Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-86.
11. CDC. Reported Tuberculosis in the United States, 2011. Atlanta, GA: U.S. Department of Health and Human Services, CDC, October 2012.
12. Ha YE, Joo EJ, Park S.Y., et al Tacrolimus as a risk factor for tuberculosis and outcome of treatment with rifampicin in solid organ transplant recipients. Transpl Infect Dis 2012; 14: 626-34.
13. Vandermarliere A, Van Audenhove A, Peetermans WE, Vanrenterghem Y, Maes B. Mycobacterial infection after renal transplantation in a Western population. Transpl Infect Dis 2003; 5: 9-15.
14. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161(4 Pt 2): S221-47.
15. Hickey MD, Quan DJ, Chin-Hong PV, Roberts JP Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver. Transplantation Society 2013; 19: 457-61.
16. Aguado JM, Herrero JA, Gavalda J, et al Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997; 63: 1278-86.
17. Holty JE, Gould MK, Meinke L, Keeffe E.B., Ruoss SJ Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl 2009; 15: 894-906.
18. Waitt CJ, Squire SB A systematic review of risk factors for death in adults during and after tuberculosis treatment. Int J Tuberc Lung Dis 2011; 15: 871-85.
19. Kesten S, Chaparro C. Mycobacterial infections in lung transplant recipients. Chest 1999; 115: 741-5.
20. Bravo C, Roldan J, Roman A., et al Tuberculosis in lung transplant recipients. Transplantation 2005; 79: 59-64.
21. Mazurek GH, Jereb J, Vernon A., et al Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection-United States, 2010. MMWR Recomm Rep 2010; 59(RR-5): 1-25.
22. Rogerson TE, Chen S, Kok J., et al Tests for latent tuberculosis in people with ESRD: a systematic review. Am J Kidney Dis 2012; 61: 33-43.
23. Theodoropoulos N, Lanternier F, Rassiwala J., et al Use of the Quanti-FERON-TB Gold interferon-gamma release assay for screening transplant candidates: a single-center retrospective study. Transpl Infect Dis 2012; 14: 1-8.
24. Milburn H, Ashman N, Davies P., et al Guidelines for the prevention and management of Mycobacterium tuberculosis infection and disease in adult patients with chronic kidney disease. Thorax Jun 2010; 65: 557-70.
25. Hill PC, Jackson-Sillah DJ, Fox A., et al Incidence of tuberculosis and the predictive value of ELISPOT and Mantoux tests in Gambian case contacts. PLoS One 2008; 3: e1379.
26. Bartalesi F, Vicidomini S, Goletti D., et al QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009; 33: 586-93.
27. Winthrop KL, Weinblatt ME, Daley CL You can't always get what you want, but if you try sometimes (with two tests-TST and IGRA-for tuberculosis) you get what you need. Ann Rheum Dis 2012; 71: 1757-60.
28. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS One 2009; 4: e8517.
29. Lyu J, Lee SG, Hwang S, et al Chest computed tomography is more likely to show latent tuberculosis foci than simple chest radiography in liver transplant candidates. Liver Transpl 2011; 17: 963-8.
30. Field M, Clarke A, Kelleher M., et al Anti-tuberculosis prophylaxis following renal transplantation: acceptable variations? Transpl Infect Dis 2012; 14: 551-4.
31. Currie AC, Knight SR, Morris PJ Tuberculosis in renal transplant recipients: the evidence for prophylaxis. Transplantation 2010; 90: 695-704.
32. Saukkonen JJ, Cohn DL, Jasmer R.M., et al An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006; 174: 935-52.
33. Benito N, Sued O, Moreno A., et al Diagnosis and treatment of latent tuberculosis infection in liver transplant recipients in an endemic area. Transplantation 2002; 74: 1381-6.
34. Jafri SM, Singal AG, Kaul D, Fontana RJ Detection and management of latent tuberculosis in liver transplant patients. Liver Transpl 2011; 17: 306-14.
35. Hall CM, Willcox PA, Swanepoel C.R., Kahn D., Van Zyl Smit R. Mycobacterial infection in renal transplant recipients. Chest 1994; 106: 435-9.
36. Sterling TR, Villarino ME, Borisov A.S., et al Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 2011; 365: 2155-66.
37. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22(SUPPL. 1): S50-4.
38. Loeliger A, Suthar AB, Ripin D, et al Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? Int J Tuberc Lung Dis 2012; 16: 6-15.
39. Horne DJ, Spitters C, Narita M. Experience with rifabutin replacing rifampin in the treatment of tuberculosis. Int J Tuberc Lung Dis 2011; 15: 1485-9, i.
40. Winthrop KL, Kubak BM, Pegues D.A., et al Transmission of Mycobacterium tuberculosis via lung transplantation. Am J Transplant 2004; 4: 1529-33.
41. Ison MG, Nalesnik MA An update on donor-derived disease transmission in organ transplantation. Am J Transplant 2011; 11: 1123-30.
42. Centers for Disease Control and Prevention. Transplantation-transmitted tuberculosis-Oklahoma and Texas, 2007. MMWR Morb Mortal Wkly Rep 2008; 57: 333-6.
43. Morris MI, Daly JS, Blumberg E, et al Diagnosis and Management of Tuberculosis in Transplant Donors: A Donor-Derived Infections Consensus Conference Report(dagger). American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2012; 12: 2288-300.
44. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58: 7-10.
45. Rose G. The risk of tuberculosis transmission in solid organ transplantation: is it more than a theoretical concern? Can J Infect Dis Med Microbiol 2005; 16: 304-8.
46. Fischer SA, Avery RK; AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2009; 9(SUPPL. 4): S7-18.
47. Jasmer RM, Bozeman L, Schwartzman K., et al Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004; 170: 1360-6.
48. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M., Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis 2003; 3: 282-7.
49. Chang KC, Leung CC, Yew W.W., Ho SC, Tam CM A nested casecontrol study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004; 170: 1124-30.
50. Panjabi R, Comstock GW, Golub JE Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007; 11: 828-37.
51. Grauhan O, Lohmann R, Lemmens P., et al Mycobacterial infection after liver transplantation. Langenbecks Arch Chir 1995; 380: 171-5.
52. Riska H, Gronhagen-Riska C, Ahonen J. Tuberculosis and renal allograft transplantation. Transplant Proc 1987; 19: 4096-7.
53. Meyers BR, Papanicolaou GA, Sheiner P, Emre S., Miller C. Tuberculosis in orthotopic liver transplant patients: increased toxicity of recommended agents; cure of disseminated infection with nonconventional regimens. Transplantation 2000; 69: 64-9.